255 related articles for article (PubMed ID: 24286213)
41. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
Henning RJ; Bourgeois M; Harbison RD
Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
[TBL] [Abstract][Full Text] [Related]
42. Small lipid-binding proteins in regulating endothelial and vascular functions: focusing on adipocyte fatty acid binding protein and lipocalin-2.
Wang Y
Br J Pharmacol; 2012 Feb; 165(3):603-21. PubMed ID: 21658023
[TBL] [Abstract][Full Text] [Related]
43. Serum midkine as a predictor of cardiac events in patients with chronic heart failure.
Kitahara T; Shishido T; Suzuki S; Katoh S; Sasaki T; Ishino M; Nitobe J; Miyamoto T; Miyashita T; Watanabe T; Takeishi Y; Kubota I
J Card Fail; 2010 Apr; 16(4):308-13. PubMed ID: 20350697
[TBL] [Abstract][Full Text] [Related]
44. Sarcolemmal dependence of cardiac protection and stress-resistance: roles in aged or diseased hearts.
See Hoe LE; May LT; Headrick JP; Peart JN
Br J Pharmacol; 2016 Oct; 173(20):2966-91. PubMed ID: 27439627
[TBL] [Abstract][Full Text] [Related]
45. Effects of Cardiovascular Risk Factors on Cardiac STAT3.
Pipicz M; Demján V; Sárközy M; Csont T
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30424579
[TBL] [Abstract][Full Text] [Related]
46. Midkine exacerbates pressure overload-induced cardiac remodeling.
Netsu S; Shishido T; Kitahara T; Honda Y; Funayama A; Narumi T; Kadowaki S; Takahashi H; Miyamoto T; Arimoto T; Nishiyama S; Watanabe T; Woo CH; Takeishi Y; Kubota I
Biochem Biophys Res Commun; 2014 Jan; 443(1):205-10. PubMed ID: 24291499
[TBL] [Abstract][Full Text] [Related]
47. Inhibitory effect of midkine-binding peptide on tumor proliferation and migration.
Huang HL; Shen JF; Min LS; Ping JL; Lu YL; Dai LC
Int J Clin Exp Pathol; 2015; 8(5):5387-94. PubMed ID: 26191241
[TBL] [Abstract][Full Text] [Related]
48. The growth factor Midkine antagonizes VEGF signaling in vitro and in vivo.
van der Horst EH; Frank BT; Chinn L; Coxon A; Li S; Polesso F; Slavin A; Ruefli-Brasse A; Wesche H
Neoplasia; 2008 Apr; 10(4):340-7. PubMed ID: 18392135
[TBL] [Abstract][Full Text] [Related]
49. Midkine is expressed by infiltrating macrophages in in-stent restenosis in hypercholesterolemic rabbits.
Narita H; Chen S; Komori K; Kadomatsu K
J Vasc Surg; 2008 Jun; 47(6):1322-9. PubMed ID: 18353604
[TBL] [Abstract][Full Text] [Related]
50. Circulating midkine in Crohn's disease: clinical implications.
Krzystek-Korpacka M; Neubauer K; Matusiewicz M
Inflamm Bowel Dis; 2010 Feb; 16(2):208-15. PubMed ID: 19572374
[TBL] [Abstract][Full Text] [Related]
51. Antisense oligodeoxyribonucleotide as to the growth factor midkine suppresses neointima formation induced by balloon injury.
Hayashi K; Banno H; Kadomatsu K; Takei Y; Komori K; Muramatsu T
Am J Physiol Heart Circ Physiol; 2005 May; 288(5):H2203-9. PubMed ID: 15637123
[TBL] [Abstract][Full Text] [Related]
52. The effects of early exercise on brain damage and recovery after focal cerebral infarction in rats.
Matsuda F; Sakakima H; Yoshida Y
Acta Physiol (Oxf); 2011 Feb; 201(2):275-87. PubMed ID: 20726846
[TBL] [Abstract][Full Text] [Related]
53. Midkine secretion protects Hep3B cells from cadmium induced cellular damage.
Yazihan N; Ataoglu H; Akcil E; Yener B; Salman B; Aydin C
World J Gastroenterol; 2008 Jan; 14(1):76-80. PubMed ID: 18176965
[TBL] [Abstract][Full Text] [Related]
54. Midkine Deteriorates Cardiac Remodeling via Epidermal Growth Factor Receptor Signaling in Chronic Kidney Disease.
Honda Y; Shishido T; Takahashi T; Watanabe T; Netsu S; Kinoshita D; Narumi T; Kadowaki S; Nishiyama S; Takahashi H; Arimoto T; Miyamoto T; Kishida S; Kadomatsu K; Takeishi Y; Kubota I
Hypertension; 2016 May; 67(5):857-65. PubMed ID: 26975703
[TBL] [Abstract][Full Text] [Related]
55. Evaluation of expression of midkine in oral squamous cell carcinoma and its correlation with tumour angiogenesis.
Ruan M; Ji T; Wu Z; Zhou J; Zhang C
Int J Oral Maxillofac Surg; 2007 Feb; 36(2):159-64. PubMed ID: 17110085
[TBL] [Abstract][Full Text] [Related]
56. Midkine regulation of the renin-angiotensin system.
Kadomatsu K
Curr Hypertens Rep; 2010 Apr; 12(2):74-9. PubMed ID: 20424942
[TBL] [Abstract][Full Text] [Related]
57. Vascular endothelial growth factor (VEGF) - part 1: in physiology and pathophysiology.
Kajdaniuk D; Marek B; Borgiel-Marek H; Kos-Kudła B
Endokrynol Pol; 2011; 62(5):444-55. PubMed ID: 22069106
[TBL] [Abstract][Full Text] [Related]
58. Exercise, vascular wall and cardiovascular diseases: an update (Part 1).
Leung FP; Yung LM; Laher I; Yao X; Chen ZY; Huang Y
Sports Med; 2008; 38(12):1009-24. PubMed ID: 19026018
[TBL] [Abstract][Full Text] [Related]
59. Combinational antitumor effect of siRNA against midkine and paclitaxel on growth of human prostate cancer xenografts.
Takei Y; Kadomatsu K; Goto T; Muramatsu T
Cancer; 2006 Aug; 107(4):864-73. PubMed ID: 16832814
[TBL] [Abstract][Full Text] [Related]
60. Growth factor Midkine is involved in the pathogenesis of renal injury induced by protein overload containing endotoxin.
Kato K; Kosugi T; Sato W; Arata-Kawai H; Ozaki T; Tsuboi N; Ito I; Tawada H; Yuzawa Y; Matsuo S; Kadomatsu K; Maruyama S
Clin Exp Nephrol; 2011 Jun; 15(3):346-354. PubMed ID: 21360016
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
